CRG

CRG is a market pioneer and innovator in healthcare investing that focuses on intellectual property investments in biopharmaceutical assets.

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Detailed CRG Information

Geographic Data

CRG headquarters map

Address:

City:

State:

Zip:

Country:

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

3,924,917Website Global Rank

3,092Website Monthly Traffic

Twitter Followers

Description

CRG is a market pioneer and innovator in healthcare investing that focuses on intellectual property investments in FDA-approved biopharmaceutical assets through royalty bonds, structured debt, revenue interests, and traditional royalty monetizations. The company targets investments between $20 and $200 million and works directly with leading healthcare companies, research institutions, and inventors to provide customized financing structures to meet their unique needs. Its financings are an attractive alternative to costly equity financings and restrictive debt financings. CRG helps healthcare organizations fund pipeline development, make acquisitions, and expand into new markets—all with an adaptable source of capital. Capital Royalty strives to help biopharma companies access capital that has little to no dilution. While much of the capital that we invest allows our counterparties to fund innovative research and development products, our primary source of collateral is derived from commercialized products. As the only investment team with experience in structuring royalty bonds, structured debt, and traditional royalty monetizations, Capital Royalty is uniquely qualified to meet a broad range of financing needs for healthcare companies. CRG provides superior risk-adjusted returns to our investors by offering the most attractive financing alternatives to our business partners. Its investors include pension funds, insurance companies, family offices, university endowments, foundations, financial institutions, and other institutional investors.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
12/2014 Nevro Debt Financing 50M
5/2015 Navidea Biopharmaceuticals Post-IPO Debt 60M
1/2016 Benvenue Medical Debt Financing 60M
11/2013 Solta Medical Post-IPO Equity 40M
12/2016 Intrinsic Therapeutics Venture Round 17.9M
12/2012 Corium International Convertible Note 45M
5/2016 Valeritas Venture Round -
5/2021 NavaDerm Debt Financing 30M
10/2014 Astute Medical Debt Financing 40M
11/2016 Omeros Post-IPO Debt 125M
2/2013 TriVascular Debt Financing 96M
1/2013 Tandem Diabetes Care Debt Financing 80M
7/2017 Strongbridge Biopharma Post-IPO Debt 50M
6/2018 Fast Pace Health Private Equity Round -
2/2017 BioDelivery Sciences Post-IPO Debt -
5/2015 Ceterix Orthopaedics Debt Financing 35M
7/2017 Strongbridge Biopharma Post-IPO Equity 3M
12/2016 T2 Biosystems Post-IPO Debt 50M
5/2014 AFT Pharmaceuticals Debt Financing 53M
3/2015 TearLab Post-IPO Debt 35M
7/2022 Calyxo Series C 32.7M
1/2016 Realeve Debt Financing -
3/2019 Harmony Biosciences Debt Financing 200M
9/2016 Access TeleCare Debt Financing 45M
7/2016 US WorldMeds Venture Round -
11/2018 HNI Healthcare Private Equity Round 65M
1/2017 EndoCeutics Debt Financing 85M
4/2014 NanoString Technologies Post-IPO Debt 45M
2/2019 EyePoint Pharmaceuticals Debt Financing 60M
2/2018 Dynavax Technologies Post-IPO Debt 175M
6/2016 Iroko Pharmaceuticals Debt Financing 140M
10/2013 Exagen Series D 5M
9/2015 Avinger Post-IPO Equity 55M
10/2014 Blue Belt Technologies Debt Financing 44M
10/2015 Silk Road Medical Private Equity Round 57M
5/2019 Aerin Medical Debt Financing 50M
1/2015 Imaging Advantage Private Equity Round 250M
6/2015 ViewRay Post-IPO Debt 50M
6/2013 Valeritas Debt Financing 100M
6/2016 Cardiome Pharma Post-IPO Debt 30M
5/2017 Viveve Post-IPO Debt 30M
7/2014 Exagen Debt Financing 4M
11/2013 Exagen Debt Financing 25M
9/2017 Synergy Pharmaceuticals Post-IPO Debt 300M
1/2015 Imaging Advantage Debt Financing -
8/2020 Treace Medical Concepts Debt Financing 50M
9/2015 GenomeDx Biosciences Debt Financing -
6/2017 Earlens Debt Financing 45M
5/2013 Good Start Genetics Debt Financing 28M
1/2019 Mid-Atlantic Dental Partners Venture Round 70M
12/2016 Hicuity Health Debt Financing 2M
6/2015 Outset Medical Debt Financing 45M
5/2012 Bioniche Pharma Group Debt Financing 20M
1/2014 Biodesix Debt Financing 20M
7/2017 Silk Road Medical Series C 0
9/2013 RainDance Technologies Debt Financing 35M
6/2018 EndoGastric Solutions Series I 0
10/2018 Earlens Series D 0
12/2015 EndoGastric Solutions Venture Round 0
6/2017 Earlens Series C 0
7/2022 Calyxo Series C 0
5/2021 NavaDerm Debt Financing 0
8/2020 Treace Medical Concepts Debt Financing 0
5/2019 Aerin Medical Debt Financing 0
3/2019 Harmony Biosciences Debt Financing 0
2/2019 EyePoint Pharmaceuticals Debt Financing 0
1/2019 Mid-Atlantic Dental Partners Venture Round 0
11/2018 HNI Healthcare Private Equity Round 0
10/2018 Earlens Series D 0
6/2018 EndoGastric Solutions Series I 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research